The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

EHA-SWG 2017 | Rare Lymphomas: CAR T-cells in Non-Hodgkin Lymphoma

Mar 22, 2017

On March 12 th, at the EHA-SWG Rare Lymphomas Scientific Meeting 2017in Barcelona, Spain, Marie José Kerstenchaired a scientific session on ‘Fighting Lymphoma with T-cells’. The first presentation of this session was by Catherine Bollard, from The George Washington University, School of Medicine and Health Sciences, Bethesda, USA, on the topic of ‘CD19 CAR T-cells for Lymphoma’. Below are the key highlights from this presentation:

  • Over 15 studies open using CAR CD19-transduced T-cells in the US
  • First generation CAR T-cells had low persistence in patients
  • Second generation CARs developed which include an additional domain, either:
    • CD28
    • 41BBL
    • OX40L
  • Second generation CAR T-cell therapy shown to have increased proliferation and persistence vs. first generation within the same B-cell lymphoma patients
  • Multiple companies are currently working on different second-generation CAR constructs e.g. Kite, Novartis, Juno, and Bluebird Bio
  • Persistence of CAR T-cells correlated with response
  • Pre-CAR T-cell lymphodepleting chemotherapy with fludarabine and cyclophosphamide improves CAR T-cell proliferation and persistence
  • Cytokine release syndrome remains an important adverse event to monitor and manage in patients undergoing CAR T-cell therapy

To summarize, Catherine Bollard presented data detailing the differences between first and second-generation CAR T-cell technology, outlined the perceived importance of CAR T-cell persistence, identified the main CAR T-cell constructs currently being used, and outlined potential issues in the applicability of this treatment. Studies are ongoing, and long-term follow-up data is eagerly being awaited.

  1. Bollard C.CAR T-cells. 2017 Mar 12. EHA-SWG Rare Lymphomas. Barcelona, Spain.